Is Concord Biotech the Best Stock in Its Sector? A Look at the Numbers
- October 15, 2026
- Posted by: Ankit Jaiswal
- Category: Market
Concord Biotech CMP Rs 1,382 (15 Oct 2026). Market cap Rs 14,449 Cr. ROE 12.94%. P/E 52.96x versus Industry P/E 36.77x.
Quick Answer
Concord Biotech is one of the names investors compare when screening the Pharmaceuticals sector. Whether it is the best stock in its sector depends on whether an investor prioritises return ratios, valuation or balance sheet strength. This article sets it against two named peers and the sector benchmark so you can judge for yourself.
Is Concord Biotech the best stock in its sector? The stock trades on the NSE at Rs 1,382 as of 15 October 2026, within its 52-week range of Rs 987.00 to Rs 1,615.00. The sections below cover the business, the key ratios, a peer comparison and a closer look at valuation.
Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers
Click Here – Get Free Investment Predictions
About Concord Biotech
Concord Biotech Ltd, based in Ahmedabad, makes active pharmaceutical ingredients through fermentation. Its range includes immunosuppressants and anti infective ingredients sold to pharmaceutical companies in regulated markets, and it also has a formulations business. At a market capitalisation of Rs 14,449 Cr, it is tracked as part of the Pharmaceuticals sector on Univest.
Is Concord Biotech the Best Stock in Its Sector?
Concord Biotech’s case in the sector rests on return quality rather than cheap valuation, since the stock trades at a premium to its Industry P/E. Concord Biotech’s 52.96x P/E is above the 36.77x Industry P/E, Neuland Laboratories at 52.07x and Marksans Pharma at 27.32x, while its 12.94% ROE is lower than Neuland Laboratories at 19.42% and Marksans Pharma at 13.82%, and its debt to equity ratio of 0.00 is below Neuland Laboratories at 0.16 and Marksans Pharma at 0.11.
| Metric | Concord Biotech |
|---|---|
| CMP (NSE) | Rs 1,382.10 |
| 52-Week High / Low | Rs 1,615.00 / Rs 987.00 |
| Market Cap | Rs 14,449 Cr |
| P/E (TTM) vs Industry P/E | 52.96x vs 36.77x |
| P/B | 7.16 |
| ROE | 12.94% |
| EPS (TTM) | Rs 26.08 |
| Dividend Yield | 0.55% |
| Debt to Equity | 0.00 |
Compare Concord Biotech Against Other Pharmaceuticals Sector Stocks
How Concord Biotech Compares Against Its Pharmaceuticals Sector Peers
The table below sets Concord Biotech against 2 other Pharmaceuticals sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.
| Company | Market Cap (Rs Cr) | P/E | ROE | Debt to Equity |
|---|---|---|---|---|
| Concord Biotech | 14,449 | 52.96 | 12.94% | 0.00 |
| Neuland Laboratories | 25,917 | 52.07 | 19.42% | 0.16 |
| Marksans Pharma | 14,236 | 27.32 | 13.82% | 0.11 |
| Peer average (2 companies) | – | 39.70 | 16.62% | 0.14 |
Measured against the peer averages, Concord Biotech’s P/E is 33 percent above the 39.70x average, and its ROE is 3.68 percentage points below the 16.62% average. An average of just two companies is a rough guide, so treat the gap as a pointer for further research and not as a verdict.
What Makes Concord Biotech Worth Watching in Pharmaceuticals
- Scale: At Rs 14,449 Cr, its market capitalisation is larger than Marksans Pharma (Rs 14,236 Cr), though smaller than Neuland Laboratories (Rs 25,917 Cr), which is a useful reminder that the peers differ in size as well as in valuation.
- Sector drivers: Demand for transplant and anti infective medicines, along with regulatory approvals in major markets, supports its ingredient sales.
- Key risk: The valuation already prices in strong growth, and any slowdown in approvals or global demand could hurt sentiment.
Concord Biotech Valuation: Is It Justified?
At a P/B ratio of 7.16, the market pays about Rs 7.16 for every rupee of book value, and the EPS (TTM) of Rs 26.08 is the earnings base behind the P/E. The stock trades about 14 percent below its 52-week high and about 40 percent above its 52-week low. The dividend yield of 0.55% is a modest income component, so returns depend mainly on the share price. As with any single stock, investors should weigh these figures against their own valuation discipline and risk appetite rather than the sector label alone.
Also read – Is Oracle Financial Services Software the Best Stock in Its Sector? A Look at the Numbers
Download the Univest iOS App or Univest Android App to track Concord Biotech and other Pharmaceuticals sector stocks.
How to Track Concord Biotech Before You Invest
Before deciding whether Concord Biotech deserves its label as the best stock in its sector for your own portfolio, compare it directly against Pharmaceuticals sector peers using the steps below.
- Open the Univest Screener and search for Concord Biotech to view live price, valuation ratios, and peer comparisons within the Pharmaceuticals sector.
- Compare its P/E, P/B, and ROE against other Pharmaceuticals sector stocks before deciding if the current valuation fits your strategy.
- Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
- Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.
Conclusion
Concord Biotech gives investors a clear set of numbers to work with, from returns and valuation to leverage and peer standing. Whether it earns the label of best stock in Pharmaceuticals depends on how much weight you give each of them and on how the business executes from here. Because the stock trades above its sector benchmark, execution matters more than usual if the current valuation is to hold. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Is Concord Biotech the best stock in its sector?
Ans. There is no single definitive answer, because the best stock in a sector depends on whether an investor is prioritising returns, valuation or balance sheet strength. Concord Biotech has a 12.94% ROE and trades at 52.96x P/E against a 36.77x Industry P/E. Against the 2 peers compared in this article, its ROE is below the 16.62% peer average and its P/E is above the 39.70x peer average. Its debt to equity ratio of 0.00 is below the 0.14 peer average, which matters because borrowing can inflate returns and add risk when business conditions weaken. These figures are best read together rather than in isolation, and they work as a starting point for your own research and not as a verdict.
What is the current share price of Concord Biotech?
Ans. Concord Biotech was trading at Rs 1,382.10 on the NSE as of 15 October 2026, and its 52-week range runs from Rs 987.00 to Rs 1,615.00. That leaves the share price 14 percent short of the 52-week high and 40 percent clear of the 52-week low. Its market capitalisation is Rs 14,449 Cr and its EPS (TTM) is Rs 26.08, which is the earnings figure behind the 52.96x P/E. Share prices change through the trading day, so check the live quote on Univest before acting on any number here.
What sector does Concord Biotech belong to?
Ans. Concord Biotech is classified under the Pharmaceuticals sector on Univest, and that group of listed companies is the reference point for the 36.77x Industry P/E used in this article. The 2 named peers compared here are Neuland Laboratories and Marksans Pharma, chosen as comparable listed names so that the P/E, ROE and debt figures come from the same live data source. Investors who want a wider view can compare more Pharmaceuticals sector stocks on the Univest Screener, since no two companies in a sector have exactly the same business mix.
How does Concord Biotech compare to its sector peers on P/E?
Ans. Concord Biotech’s P/E of 52.96x is above the 39.70x average of the 2 named peers, with Neuland Laboratories at 52.07x and Marksans Pharma at 27.32x. It also sits above the 36.77x Industry P/E, which is the benchmark for the wider Pharmaceuticals sector. A P/E that is above a peer average can reflect a valuation discount or premium, but it can also reflect different growth or return expectations, so it should be read alongside ROE and debt. Its P/B ratio of 7.16 gives one more view of how the market values its book value.
What is Concord Biotech’s return on equity?
Ans. Concord Biotech reported a return on equity of 12.94%, which is below the 16.62% average of its named peers, with Neuland Laboratories at 19.42% and Marksans Pharma at 13.82%. ROE shows how much profit a company generates on every rupee of shareholders’ equity, so a higher figure generally points to more efficient use of capital. ROE is easier to trust when leverage is modest, and here the debt to equity ratio is 0.00 against a peer average of 0.14. It is worth checking whether the ROE has been stable over several years rather than relying on a single reading.
Should I invest in Concord Biotech based on its sector position?
Ans. Sector position is only one input into an investment decision. Concord Biotech has a 12.94% ROE and a 52.96x P/E, which make it worth researching further, and its dividend yield is 0.55%. You should also weigh its business outlook, earnings consistency, debt levels, your investment horizon and your own risk appetite before buying. Spreading money across several stocks and sectors reduces concentration risk, and this article is educational content, not investment advice. For personalised guidance, consult a SEBI-registered advisor.
